- Home
- LIQT vs SABS Comparison
LIQT vs SABS Comparison
Compare LIQT & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIQT
- SABS
- Stock Information
- Founded
- LIQT 2004
- SABS 2014
- Country
- LIQT Denmark
- SABS United States
- Employees
- LIQT N/A
- SABS N/A
- Industry
- LIQT Industrial Machinery/Components
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- LIQT Technology
- SABS Health Care
- Exchange
- LIQT Nasdaq
- SABS Nasdaq
- Market Cap
- LIQT 16.1M
- SABS 15.8M
- IPO Year
- LIQT N/A
- SABS N/A
- Fundamental
- Price
- LIQT $1.70
- SABS $1.78
- Analyst Decision
- LIQT Strong Buy
- SABS Strong Buy
- Analyst Count
- LIQT 2
- SABS 5
- Target Price
- LIQT $4.80
- SABS $11.80
- AVG Volume (30 Days)
- LIQT 15.9K
- SABS 18.6K
- Earning Date
- LIQT 08-13-2025
- SABS 08-07-2025
- Dividend Yield
- LIQT N/A
- SABS N/A
- EPS Growth
- LIQT N/A
- SABS N/A
- EPS
- LIQT N/A
- SABS N/A
- Revenue
- LIQT $14,986,815.00
- SABS $377,835.00
- Revenue This Year
- LIQT $36.89
- SABS N/A
- Revenue Next Year
- LIQT $16.33
- SABS N/A
- P/E Ratio
- LIQT N/A
- SABS N/A
- Revenue Growth
- LIQT N/A
- SABS N/A
- 52 Week Low
- LIQT $1.34
- SABS $1.00
- 52 Week High
- LIQT $3.20
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- LIQT 52.96
- SABS 49.33
- Support Level
- LIQT $1.58
- SABS $1.60
- Resistance Level
- LIQT $1.64
- SABS $1.87
- Average True Range (ATR)
- LIQT 0.09
- SABS 0.11
- MACD
- LIQT -0.01
- SABS -0.01
- Stochastic Oscillator
- LIQT 44.83
- SABS 62.07
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.